MLTX

Announcements

Nothing here yet

Daily updates

• Sonelokimab Phase 3 trial achieved all Week 16 clinical endpoints in psoriatic arthritisAug 10, 2026

FDA designations

Nothing here yet

News

• MoonLake announced positive topline Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis, demonstrating significant improvements across all clinical endpointsAug 10, 2026
• MoonLake Immunotherapeutics reports positive outcome from final pre-BLA meeting with FDAMay 11, 2026
• MoonLake received FDA Fast Track for sonelokimab in palmoplantar pustulosisFeb 2, 2026
• MoonLake Immunotherapeutics reported positive FDA Type B meeting outcomeJan 8, 2026
• MoonLake Immunotherapeutics reports week 16 results of VELA Phase 3 hidradenitis suppurativa program with Nanobody® sonelokimabSep 29, 2025